Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 2/20 | 0.44 |
| ▸ | WNT3A | P56704 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.36 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.36 |
| ▸ | RBP4 | P02753 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11920844 | 0.77 | CTNNB1 (0.51) | CTNNB1WNT3AGAANFE2L2HSD11B1 | |
| SCHEMBL4366167 | 0.74 | CTNNB1 (0.51) | CTNNB1WNT3AGAANFE2L2HSD11B1 | |
| SCHEMBL29365642 | 0.74 | CTNNB1 (0.51) | CTNNB1WNT3AGAANFE2L2HSD11B1 | |
| SCHEMBL286833 | 0.73 | KDM4E (0.55) | CTNNB1WNT3ANFE2L2HSD11B1HCRTR1 | |
| SCHEMBL5325529 | 0.73 | CTNNB1 (0.46) | CTNNB1WNT3AGAANFE2L2HSD11B1 | |
| Hydrochloric Acid SCHEMBL23354263 | 0.73 | CTNNB1 (0.50) | CTNNB1WNT3AGAANFE2L2HSD11B1 | |
| Bromide SCHEMBL4353378 | 0.73 | CTNNB1 (0.50) | CTNNB1WNT3AGAANFE2L2HSD11B1 | |
| Hydrochloric Acid SCHEMBL29978860 | 0.73 | CTNNB1 (0.50) | CTNNB1WNT3AGAANFE2L2HSD11B1 | |
| Hydrochloric Acid SCHEMBL1981601 | 0.73 | CTNNB1 (0.50) | CTNNB1WNT3AGAANFE2L2HSD11B1 | |
| SCHEMBL1981639 | 0.72 | CTNNB1 (0.47) | CTNNB1WNT3ANFE2L2HSD11B1HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152326-A1 | SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS | HANAZAWA TAKESHI | 2011-06-23 | — | — | US | disclosed |
| WO-2006016218-A1 | ARYL OR HETEROARYL CARBONYL DERIVATIVES DERIVATIVES USEFUL AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152326-A1 | SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS | OPRL1, CNR1, TRPV1 | CTNNB1 480/4885WNT3A 1780/4885GAA 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.